製品番号: HY-N2332A

Methyllycaconitine citrate

Name: Methyllycaconitine citrate
Brand: MedChemExpress
SKU: HY-N2332A
Price: 70.00 USD
Availability: InStock
Rating: 5 (55 reviews)

(別名: MLA citrate)

55 Cited Publications

カスタマーレビュー

Based on 55 publication(s) in Google Scholar

Methyllycaconitine (MLA) citrate is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor (α7nAChR) with an IC₅₀ of 2 nM. Methyllycaconitine citrate inhibits Aβ_25-35-induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species (ROS) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine citrate induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine citrate can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度 : 98.88%
CAS 番号: 351344-10-0
分子式: C₄₃H₅₈N₂O₁₇
分子量:874.92

保管条件:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Methyllycaconitine citrate 構造式

CAS 番号: 351344-10-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (55)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

α7nAChR^[1]

mTOR アイソフォーム固有の製品をすべて表示 :

体外実験

Aβ/Tau/α-Synuclein AggregationAutophagyOthersOxidative Stress

Aβ/Tau/α-Synuclein Aggregation

Methyllycaconitine (2.5-20 μM; 24 h) shows no cytotoxicity against SH-SY5Y cells and alleviates Aβ_25-35-induced cytotoxicity in SH-SY5Y cells^[1].

Autophagy

Methyllycaconitine (5 μM) inhibits Aβ_25-35-induced autophagy in SH-SY5Y cells by reducing LC3-II accumulation, autophagosome formation, and acidic vacuole formation^[1].

Others

Methyllycaconitine (5 μM) inhibits Aβ_25-35-induced autophagy in SH-SY5Y cells by restoring mTOR pathway activity^[1].
Methyllycaconitine (0.1 μM; 40 min) inhibits the methamphetamine-induced suppression of [³H]dopamine uptake in mouse striatal synaptosomes without altering the basal uptake level^[2].
Methyllycaconitine (5 nM-50 μM; 3 min) does not alter vesicular uptake of [³H]dopamine in isolated mouse striatal synaptic vesicles^[2].
Methyllycaconitine (1 nM; 2 min) potently inhibits agonist responses of human α7 nicotinic acetylcholine receptors heterologously expressed in Xenopus laevis oocytes, reducing the normalized response to 3.4% at a concentration of 1 nM^[3].
Methyllycaconitine potently competes with [¹²⁵I]α-bungarotoxin for binding to α7 nicotinic acetylcholine receptors in rat brain, with an IC₅₀ of 0.01 μM^[3].
Methyllycaconitine inhibits nicotine-induced catecholamine secretion in bovine adrenal cells expressing α3β4 nicotinic acetylcholine receptors, with an inhibition rate of approximately 95%^[3].

Oxidative Stress

Methyllycaconitine (1-50 μM; 2.25 h) inhibits methamphetamine-induced reactive oxygen species production in mouse striatal synaptosomes in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human neuroblastoma SH-SY5Y cells
Concentration:

2.5 μM, 5 μM, 10 μM, 20 μM (administered alone); 2.5 μM, 5 μM, 10 μM (pretreatment for Aβ_25-35-induced cytotoxicity)
Incubation Time:

24 h (administered alone)
Result:

Did not reduce SH-SY5Y cell viability relative to control cells at concentrations of 2.5, 5, 10, and 20 μM when administered alone.
Significantly inhibited the decrease in cell viability induced by 10 μM Aβ_25-35 at 5 and 10 μM pretreatment.
Showed a protective trend against Aβ_25-35-induced cytotoxicity at 2.5 μM pretreatment.

体内実験

OthersInnate ImmunityGlutamate Release or Receptors

Others

Methyllycaconitine (6 mg/kg; i.p.; single administration) inhibits methamphetamine-induced climbing behavior in male Swiss CD-1 mice by 50%^[2].
Methyllycaconitine (0.003-0.1 mg/kg; i.p.; single administration) significantly enhances the long-term memory acquisition ability of healthy male Wistar rats in the object recognition task (ORT) with a 24 h retention period^[4].

Innate Immunity

Methyllycaconitine (6 mg/kg; i.p.; administered 4 times total) attenuates Methamphetamine-induced loss of striatal dopaminergic terminals in male Swiss CD-1 mice by partially restoring the levels of dopamine transporter and tyrosine hydroxylase^[2].

Glutamate Release or Receptors

Methyllycaconitine (1.0 mg/kg; i.p.; single administration) significantly increases glutamate efflux in the hippocampus of healthy male Sprague Dawley rats, with the effect starting at 30 min post-injection and lasting for at least 2 h^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss CD-1 (adult male, 20-26 g, climbing behavior study)^[2]
Dosage:

6 mg/kg
Administration:

i.p.; single dose; 20 minutes prior to methamphetamine
Result:

Did not induce climbing behavior.
Significantly inhibited methamphetamine-induced climbing behavior by approximately 50%.

Animal Model:

Swiss CD-1 (adult male, 28-32 g)^[2]
Dosage:

6 mg/kg
Administration:

i.p.; four total doses; 20 minutes prior to each methamphetamine dose, administered at 2-hour intervals
Result:

Did not alter striatal dopamine transporter density, microglial activation, tyrosine hydroxylase levels, basal body temperature, or body weight.
Attenuated methamphetamine-induced loss of striatal dopamine transporters (from a 73% reduction in controls to a partial recovery to 250 fmol mg^-1).
Fully prevented methamphetamine-induced microglial activation (blocking the 53% increase in [³H]PK 11195 binding).
Attenuated methamphetamine-induced loss of striatal tyrosine hydroxylase levels (from a 90% reduction in controls to a 45% reduction).
Did not modify methamphetamine-induced hyperthermia or body weight loss.

Animal Model:

Sprague Dawley (3-month-old male)^[4]
Dosage:

0.01 mg/kg; 0.1 mg/kg; 1.0 mg/kg; 10 mg/kg
Administration:

i.p.; single dose
Result:

Significantly increased hippocampal glutamate efflux starting 30 minutes post-injection, with the effect lasting at least 2 hours.
Showed significantly higher glutamate efflux than the vehicle/control group starting 40 minutes post-injection.
Caused no significant glutamate efflux changes at doses of 0.01, 0.1, or 10 mg/kg.

Animal Model:

Wistar (3-4-month-old male)^[4]
Dosage:

0.1 mg/kg (1h retention); 0.3 mg/kg (1h retention); 1.0 mg/kg (1h retention); 0.001 mg/kg (24h retention); 0.003 mg/kg (24h retention); 0.03 mg/kg (24h retention); 0.1 mg/kg (24h retention); 0.3 mg/kg (24h retention); 1.0 mg/kg (24h retention)
Administration:

i.p.; single dose; 30 min pre-learning trial
Result:

Significantly reduced object discrimination (d2 index) compared to vehicle at 1.0 mg/kg in the 1h retention interval, with discrimination performance no longer significantly different from zero.
Significantly increased object discrimination compared to vehicle at 0.003 mg/kg, 0.03 mg/kg, and 0.1 mg/kg in the 24h retention interval.
Showed discrimination performance significantly different from chance level for doses ranging from 0.003 to 0.3 mg/kg in the 24h retention interval.
Caused no differences in exploratory behavior between treatment conditions in either retention interval.

Related Protocols :

化学情報

CAS 番号 351344-10-0
性状 Solid
分子量 874.92
分子式 C₄₃H₅₈N₂O₁₇
Color White to yellow
SMILES

CO[C@@H]1C(C(N(CC)C2)C3(O)[C@H]4OC)([C@@](C[C@@]5([H])[C@@H]6OC)([H])[C@@]6([H])[C@@]3(C[C@@H]5OC)O)[C@@]4([H])[C@@]2(COC(C7=C(N(C8=O)C(C[C@@H]8C)=O)C=CC=C7)=O)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
別名

MLA citrate
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (55)

All In Vivo ImagingWBRT-PCRHistological Imaging/StainingIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Sleep Deprivation Aggravates Periodontitis Through Trigeminal-Periodontal Neuroimmune Pathway Mediated by the AChE-ACh-α7nAChR Axis. [Abstract]

2025 Aug 14:e00945. PMID: 40810704

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 14:e00945. [Abstract]

3D reconstruction of micro-CT scanned images of the mouse alveolar bone. GTS-21 or MLA were administered in combination with EA in the LIP + SD + EA group, GTS-21 inhibited the progression of bone resorption, whereas Methyllycaconitine (MLA; 6 mg/kg; i.p. daily for 7 d) exacerbated it.

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Aug 14:e00945. [Abstract]

Mouse periodontal tissues mRNA expression of pro-inflammatory-related genes IL-1β), IL-6, TNF-α, and anti-inflammatory-related gene IL-10. LIP+SD (LIP with sleep deprivation); EA (10 Hz, 1 mA, square wave) ; GTS-21 (4 mg/kg; i.p. daily for 7 d); Methyllycaconitine (MLA; 6 mg/kg; i.p. daily for 7 d).
Cell Rep Med

2026 Sep 15;7(9):102994. PMID: 42612638
J Neuroinflammation

PVNOXT regulates acinar cell-mediated inflammatory response via DMVACh projections to the acinar cell. [Abstract]

2026 May 25. PMID: 42186091
J Neuroinflammation

Mechanisms underlying antidepressant effect of transcutaneous auricular vagus nerve stimulation on CUMS model rats based on hippocampal α7nAchR/NF-κB signal pathway. [Abstract]

2021 Dec 17;18(1):291. PMID: 34920740

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2021 Dec 17;18(1):291. [Abstract]

Immunofluorescence staining of hippocampal sections in each group rats (IL-1β). The microglia transform from ameboid form (α7nAchR(−/−) + taVNS group and Hi MLA (Methyllycaconitine; (80 μg/kg; 1-week continuous unilaterally local infusions)) + taVNS group) to ramified state (Hi saline + taVNS). Compared with α7nAchR(−/−) + taVNS group and Hi MLA + taVNS group, the co-expression between pro-inflammatory cytokine IL-1β (green) and microglia (red) decreased in Hi saline + taVNS group. IL-1β (green), Iba-1 (red), DAPI (blue), Merge (yellow).

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2021 Dec 17;18(1):291. [Abstract]

The effect of α7nAchR in the hippocampus on the body mass and behavioral experiments of CUMS rats intervened by taVNS at different time points. MLA (Methyllycaconitine; 80 μg/kg; 1-week continuous unilaterally local infusions); taVNS (transcutaneous auricular vagus nerve stimulation).
Diabetologia

α7 Nicotinic acetylcholine receptor activation rescues mitochondrial dysfunction in gestational diabetes mellitus by competing with p66Shc for VDAC1 binding. [Abstract]

2025 Dec 15. PMID: 41396300

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: Diabetologia. 2025 Dec 15. [Abstract]

Immunoblot analysis of α7nAChR after co-IP with an anti-VDAC1 antibody in HTR8/SVneo cells treated with NG (Normal glucose), HG (High glucose), HG + PNU-282987 or HG + MLA (Methyllycaconitine; 24 h).
Acta Pharmacol Sin

Vagus nerve stimulation as a promising neuroprotection for ischemic stroke via α7nAchR-dependent inactivation of microglial NLRP3 inflammasome. [Abstract]

2024 Jul;45(7):1349-1365. PMID: 38504011

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2024 Jul;45(7):1349-1365. [Abstract]

TTC staining and quantification showing the blockade of VNS-induced reduction in infarct volume in the MLA (Methyllycaconitine; 2.5 mg/kg; i.p. 1 h before tMCAO model)-treated mice subjected to tMCAO model. Scale bar: 1.0 cm, n = 6.
Cell Death Discov

Alpha-7 nicotinic acetylcholine receptor agonist alleviates psoriasis-like inflammation through inhibition of the STAT3 and NF-κB signaling pathway. [Abstract]

2022 Mar 30;8(1):141. PMID: 35351863
Cell Death Discov

Vagus nerve stimulation alleviated cerebral ischemia and reperfusion injury in rats by inhibiting pyroptosis via α7 nicotinic acetylcholine receptor. [Abstract]

2022 Feb 8;8(1):54. PMID: 35136042
Cell Death Discov

Vagus nerve stimulation enhances the cholinergic anti-inflammatory pathway to reduce lung injury in acute respiratory distress syndrome via STAT3. [Abstract]

2021 Mar 29;7(1):63. PMID: 33782389
Cell Rep

Enterobacter ludwigii protects DSS-induced colitis through choline-mediated immune tolerance. [Abstract]

2022 Aug 30;40(9):111308. PMID: 36044853
Br J Pharmacol

Cholinergic G protein-coupled bile acid receptor 1 (TGR5/GPBA) in the medial septal orchestrates adult hippocampal neurogenesis and cognition in Alzheimer's disease mice. [Abstract]

2025 Nov;182(21):5409-5429. PMID: 40926398
Neurotherapeutics

Electroacupuncture improves gastrointestinal motility through a central-cholinergic pathway-mediated GDNF releasing from intestinal glial cells to protect intestinal neurons in Parkinson's disease rats. [Abstract]

2024 Jul;21(4):e00369. PMID: 38744625
PLoS Biol

2026 Aug 3;24(8):e3003923. PMID: 42545964
J Ethnopharmacol

α7nAChR-mediated astrocytic activation: a novel mechanism of Xiongzhi Dilong decoction in ameliorating chronic migraine. [Abstract]

2024 Nov 15:334:118509. PMID: 38971346
Biochem Pharmacol

Cynandione A and PHA-543613 inhibit inflammation and stimulate macrophageal IL-10 expression following α7 nAChR activation. [Abstract]

2021 Aug:190:114600. PMID: 33992630
Life Sci

Sinomenine ameliorates myocardial ischemia/reperfusion injury by inhibiting mitochondrial oxidative stress-mediated PANoptosis and ferroptosis via α7nAChR. [Abstract]

2026 Mar 1:388:124199. PMID: 41520699
Inflamm Res

Activating α7nAChR helps post-myocardial infarction healing by regulating macrophage polarization via the STAT3 signaling pathway. [Abstract]

2023 Apr;72(4):879-892. PMID: 36912917

Methyllycaconitine citrate purchased from MedChemExpress. Usage Cited in: Inflamm Res. 2023 Apr;72(4):879-892. [Abstract]

PNU-282987 (3 mg/kg; i.p.; single daily for consecutively 28 days) signifcantly decreases the expression levels of collagen I, collagen III, and α-SMA in myocardial infarction (MI) rats model, while Methyllycaconitine citrate (MLA; 3 mg/kg; i.p.; single daily for consecutively 28 days) increases these proteins levels.
Respir Res

Activation of α7nAChR prevents maladaptive right ventricular remodeling via inhibiting the recruitment of CCR2+ macrophages in experimental pulmonary arterial hypertension. [Abstract]

2026 Apr 1;27(1):206. PMID: 41923075
Eur J Pharmacol

Administration of Huperzine A microspheres ameliorates myocardial ischemic injury via α7nAChR-dependent JAK2/STAT3 signaling pathway. [Abstract]

2023 Feb 5:940:175478. PMID: 36563953
Eur J Pharmacol

Activation of alpha7 nicotinic acetylcholine receptor protects bovine endometrial tissue against LPS-induced inflammatory injury via JAK2/STAT3 pathway and COX-2 derived prostaglandin E2. [Abstract]

2021 Jun 5:900:174067. PMID: 33811838
Int Immunopharmacol

2026 Oct 1:186:117098. PMID: 42385643
Int Immunopharmacol

2026 Oct 1:186:117153. PMID: 42470857
Int J Mol Sci

KYNA Ameliorates Glutamate Toxicity of HAND by Enhancing Glutamate Uptake in A2 Astrocytes. [Abstract]

2024 Apr 12;25(8):4286. PMID: 38673879
J Integr Med

Acupuncture alleviates inflammatory pain by regulating microglial polarization through α7nAchR-mediated autophagy. [Abstract]

2026 May;24(3):429-442. PMID: 41826216
J Integr Med

2026 Jan 28.
Eur J Pharm Sci

Intra-aortic infusion of nicotine can induce a novel mouse model of abdominal aortic aneurysm. [Abstract]

2025 Aug 1:211:107143. PMID: 40425130
Bioorg Chem

Identification of O-arylated huperzinines as novel cholinergic anti-inflammatory pathway agonists against gout arthritis. [Abstract]

2024 Nov:152:107716. PMID: 39178707
Exp Gerontol

Activation of α7nAChR by PNU282987 improves cognitive impairment through inhibiting oxidative stress and neuroinflammation in D-galactose induced aging via regulating α7nAChR/Nrf2/HO-1 signaling pathway. [Abstract]

2023 May:175:112139. PMID: 36898594
Mediators Inflamm

Nicotine Regulates LPS-Induced Inflammatory Responses in HMC3 Microglia and Exerts Neuronal Protection. [Abstract]

2026 Jan 21:2026:4652344. PMID: 41583120
Mediators Inflamm

Exploring the Mechanism on the Medullary Visceral Zone Inhibiting the Cholinergic Anti-inflammatory Pathway Induced by Sepsis. [Abstract]

2020 Sep 29:2020:1320278. PMID: 33061821
Neuropharmacology

2026 Dec 15:301:111177. PMID: 42685894
Cell Signal

The role of α7nAchR and PD-L1 in neuroimmune regulation of keloid treatment. [Abstract]

2024 Sep:121:111275. PMID: 38942343
J Inflamm Res

2026 Aug 1:19:614851. PMID: 42559398
Neurochem Res

SAM Alleviates Neuroinflammation by Regulating M1/M2 Polarization of Microglia Through α7nAChR/Nrf2/HO-1 Signaling Pathway. [Abstract]

2025 Mar 29;50(2):131. PMID: 40156718
iScience

Stimulation of TRPV1+ peripheral somatosensory nerves suppress inflammation via the somato-autonomic reflex. [Abstract]

2025 Jan 17;28(2):111831. PMID: 39967868
iScience

Targeting CD36 determines nicotine derivative NNK-induced lung adenocarcinoma carcinogenesis. [Abstract]

2023 Jul 27;26(8):107477. PMID: 37599821
Neurochem Res

S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway. [Abstract]

2021 Apr;46(4):888-904. PMID: 33481205
Ren Fail

Curcumin regulates ferroptosis by activating α7 nicotinic acetylcholine receptor to improve sepsis-induced acute kidney injury. [Abstract]

2026 Dec;48(1):2657652. PMID: 42015821
Cardiovasc Drugs Ther

Transcutaneous Auricular Vagus Nerve Stimulation Ameliorates Heart Failure with Preserved Ejection Fraction Through Regulating Macrophage Polarization Mediated by Alpha7nAChR. [Abstract]

2025 Apr 7. PMID: 40193005
Animal Model Exp Med

2026 Aug 16:10.1002/ame2.70220. PMID: 42605158
J Pain Res

The Spinal α7-Nicotinic Acetylcholine Receptor Contributes to the Maintenance of Cancer-Induced Bone Pain. [Abstract]

2021 Feb 15:14:441-452. PMID: 33623426
Neurogastroenterol Motil

Electroacupuncture at Zusanli (ST36) Alleviate Intestinal Ischemia-Reperfusion Injury by Regulating the Cholinergic-miRNA 124 Pathway. [Abstract]

2026 Jan;38(1):e14971. PMID: 39618028
J Cell Biochem

Activation of α7 Nicotinic Acetylcholine Receptor Improves Muscle Endurance by Upregulating Orosomucoid Expression and Glycogen Content in Mice. [Abstract]

2024 Sep;125(9):e30630. PMID: 39014907
Hereditas

Involvement of α7nAChR in the hepatic-protective effect of remifentanil preconditioning in ischemia/reperfusion rats. [Abstract]

2025 Dec 29;162(1):239. PMID: 41466476
Epilepsy Res

Long-term administration of EQU-001 (ivermectin) suppresses spasms in a rat model of infantile epileptic spasms syndrome. [Abstract]

2026 Jan:219:107712. PMID: 41275582
Neurosci Lett

Inhibiting specificity protein 1 attenuated sevoflurane-induced mitochondrial stress and promoted autophagy in hippocampal neurons through PI3K/Akt/mTOR and α7-nAChR signaling. [Abstract]

2023 Jan 18:794:136995. PMID: 36464148
Neurosci Lett

α7nAchR mediates transcutaneous auricular vagus nerve stimulation-induced neuroprotection in a rat model of ischemic stroke by enhancing axonal plasticity. [Abstract]

2020 Jun 21:730:135031. PMID: 32416113
bioRxiv

2026 May 20.
bioRxiv

Dual cholinergic mechanisms for sculpting striatal dopamine in vivo. [Abstract]

2025 Dec 21:2025.12.19.695021. PMID: 41446203
bioRxiv

2025 Sep 11.
Heliyon

Electroacupuncture ameliorates gastrointestinal dysfunction by modulating DMV cholinergic efferent signals to drive the vagus nerve in p-MCAO rats. [Abstract]

2024 Apr 9;10(8):e29426. PMID: 38638995
SSRN

2023 Jul 25.
Research Square Preprint

2023 May 30.
Research Square Print

September 22nd, 2022.
Research Square Preprint

2021 Apr.

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (114.30 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2.18 mg/mL (2.49 mM; Need ultrasonic and warming)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1430 mL

5.7148 mL

11.4296 mL

5 mM

0.2286 mL

1.1430 mL

2.2859 mL

10 mM

0.1143 mL

0.5715 mL

1.1430 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (2.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (300 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zheng X, et al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PloS one. 2014;9(10):e111536. [Content Brief]

[2]. Escubedo E, et al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. The Journal of pharmacology and experimental therapeutics. 2005 Nov;315(2):658-67. [Content Brief]

[3]. Qasem AMA, et al. Synthesis and Antagonist Activity of Methyllycaconitine Analogues on Human α7 Nicotinic Acetylcholine Receptors. ACS bio & med chem Au. 2023 Apr 19;3(2):147-157. [Content Brief]

[4]. van Goethem NP, et al. Antagonizing α7 nicotinic receptors with methyllycaconitine (MLA) potentiates receptor activity and memory acquisition. Cellular signalling. 2019 Oct;62:109338. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.1430 mL	5.7148 mL	11.4296 mL	28.5740 mL
DMSO	5 mM	0.2286 mL	1.1430 mL	2.2859 mL	5.7148 mL
	10 mM	0.1143 mL	0.5715 mL	1.1430 mL	2.8574 mL
	15 mM	0.0762 mL	0.3810 mL	0.7620 mL	1.9049 mL
	20 mM	0.0571 mL	0.2857 mL	0.5715 mL	1.4287 mL
	25 mM	0.0457 mL	0.2286 mL	0.4572 mL	1.1430 mL
	30 mM	0.0381 mL	0.1905 mL	0.3810 mL	0.9525 mL
	40 mM	0.0286 mL	0.1429 mL	0.2857 mL	0.7144 mL
	50 mM	0.0229 mL	0.1143 mL	0.2286 mL	0.5715 mL
	60 mM	0.0190 mL	0.0952 mL	0.1905 mL	0.4762 mL
	80 mM	0.0143 mL	0.0714 mL	0.1429 mL	0.3572 mL
	100 mM	0.0114 mL	0.0571 mL	0.1143 mL	0.2857 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Methyllycaconitine citrate

55 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Methyllycaconitine citrate

MedChemExpress（MCE）の使用を引用している文献 Methyllycaconitine citrate

mTOR アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC₅₀ & Target

体外実験

体内実験

化学情報

Publications (55)

溶剤 & 溶解度

体外:

体内:

In Vivo Dissolution Calculator

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

最近チェックした製品

Methyllycaconitine citrate

MedChemExpress（MCE）の使用を引用している文献 Methyllycaconitine citrate

mTOR アイソフォーム固有の製品をすべて表示

生物活性

製品説明

IC50 & Target

体外実験

体内実験

化学情報

Publications (55)

溶剤 & 溶解度

体外:

体内:

In Vivo Dissolution Calculator

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table